EQT Private Equity, through the EQT Mid Market Europe fund, has entered into an agreement to sell Ellab to the Danish company Novo Holdings. This is reported in the EQT press release.
EQT Private Equity acquired Ellab in September 2019 in order to expand the company's monitoring and consulting capabilities. Ellab, under the management of EQT Private Equity, has refocused on fast-growing industries, including biotechnology, cell and gene therapy, as well as contract development and manufacturing.
Ellab has invested heavily in research, development and digitalization as part of the acquisition of 15 companies and has defined a clear strategy for sustainable development through participation in the Science Based Targets initiative to develop targets for reducing greenhouse gas emissions.
The transaction is expected to be completed in the third quarter after regulatory approval.
EQT Private Equity is a global Swedish investment company with assets worth 119 billion euros under management in the business segments of private capital and real assets. EQT owns portfolio companies and assets in Europe, Asia-Pacific and the Americas
Ellab, headquartered in Hillered, Denmark, provides validation and monitoring solutions and services used to measure and document critical parameters, including temperature, pressure, and CO2 in biotechnological and pharmaceutical processes. The company's clients are 20 largest biotech companies and 40 largest pharmaceutical companies worldwide.
Novo Holdings is an asset management investment company of the Novo Nordisk Foundation. Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novozymes A/S and manages an investment portfolio with a long-term profitability perspective. The company has total assets worth 108 billion euros. The headquarters is located in Copenhagen (Denmark).
